Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Philip Mease  
Providence St. Joseph Health  

A Kavanaugh  
A Reimold  

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications  
Part of the Orthopedics Commons, and the Rheumatology Commons

Recommended Citation  
Mease, Philip; Kavanaugh, A; and Reimold, A, "Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial." (2018). Journal Articles and Abstracts. 1022.  
https://digitalcommons.psjhealth.org/publications/1022
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial


The authors noticed a potential data inconsistency in the published version. The statement regarding the tuberculosis needs to be updated in the first paragraph of the ‘Safety’ sub-section under the ‘Results’ section (page 4).

The corrected information on tuberculosis is: No new cases of tuberculosis, and noreactivation of latent tuberculosis were reported.

Open access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Author(s) or their employer(s) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

RMD Open 2018;4:e000723corr1. doi:10.1136/rmdopen-2018-000723corr1

Check for updates